Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin plus atezolizumab in previously treated advanced small cell lung cancer
2024-517705-93-00Phase 2Completed
- Sponsor
- OncoSur
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lurbinectedin and atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by OncoSur. Primary endpoints: Maximum tolerated dose, Recommended dose and 6 more. Started Dec 2019; status: completed.
02
Drugs
lurbinectedinatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-517705-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517705-93-00.